5 top TSXV clean tech and life sciences stocks to buy in June

Be the First to Comment Read

5 top TSXV clean tech and life sciences stocks to buy in June

canada junior stocks
Image source: © Solarseven | Megapixl.com

Highlights

  • Sernova Corp is in the pharmaceutical business and develops treatments for chronic debilitating disorders.
  • Compact MRI and NMR devices are developed and manufactured by Nanalysis.
  • On May 10, it was announced that Therma Bright would apply to Health Canada to get their AcuVid™ COVID-19 Rapid Antigen Saliva Test approved.

The TSX Venture Exchange (TSXV) in Canada provides a wide variety of stocks to retail investors, and generally, the stocks listed on the TSXV are budget-friendly.

Also Read: Activision soars as Berkshire ups stake: Does Buffett own TSX stocks?

Often, new investors buy stocks from the TSXV because they are cheap, and some of them have a high chance of growth and eventually graduate to the country's main stock market- Toronto Stock Exchange.

This article brings you the top clean technology and life sciences stocks on the TSXV. Here's why you may consider them for your investment portfolio in June.

Sernova Corp. (TSXV:SVA)

Sernova Corp is in the pharmaceutical business and develops treatments for chronic debilitating disorders. The company's unique Cell Pouch and related technologies, such as immune-protected therapeutic cells, are being researched and developed.

The pharmaceutical company ranked first among the 50 top performing TSXV companies. As of December 31, 2021, the SVA stock had climbed 172% year-over-year (YoY). On May 30, the SVA stock was priced at C$ 1.53 per share after surging 0.7 per cent during the trading session.

On May 17, it was announced that Sernova and Evotec have partnered to develop and commercialise an iPSC-based beta cell replacement therapy as a "functional cure" for diabetes.

Eguana Technologies Inc. (TSXV:EGT)

Eguana Technologies Inc develops and produces energy storage solutions for homes and small businesses. The company provides power electronics for fuel cell, solar, and battery applications from its manufacturing centres in North America, Australia, and Europe.

The EGT stock grew 123% in a year. Meanwhile, the market cap had surged 266% YoY to C$ 188.9 million for the 12 months ended December 31, 2021.

In Q2 2022, Eguana's product revenue was C$ 0.3 million to accelerate future funding prospects, and the company completed a C$ 150 million base shelf prospectus.

Nanalysis Scientific Corp. (TSXV:NSCI)

Compact MRI and NMR devices are developed and manufactured by Nanalysis. Devices from the firm are utilised in diagnostics and chemical analysis in a variety of industries as well as various government and university research labs throughout the world.

On May 26, Nanalysis announced that its wholly-owned subsidiary KPrime had been awarded a six-year $160 million service and maintenance contract with the Canadian Air Transportation Security Authority.

Nanalysis stock

The NSCI stock had jumped around one per cent during the trading session on May 30 and closed at C$ 1.25 per share. Meanwhile, in 2021, the stock registered a growth of 254% in comparison to the previous year.

Therma Bright Inc. (TSXV:THRM)

Therma Bright specialises in making dermatological products for medical devices. It includes a revolutionary thermal treatment technology that employs heat and light energy to offer topical comfort to skin irritations caused by bug bites and stings and cold sore prevention.

On May 10, it was announced that Therma Bright would apply to Health Canada to get their AcuVid™ COVID-19 Rapid Antigen Saliva Test approved.

The THRM stock registered a growth of 111% YoY as of December 31, 2021. It was priced at C$ 0.16 per share at market close on May 30.

Arch Biopartners Inc. (TSXV:ARCH)

Arch Biopartners is working on technologies that might have medicinal or commercial implications. The business is working on a pharmacological platform called Metablok that will let them create therapeutic candidates that will stop organ inflammation.

The company announced in February that Health Canada agreed to an amendment to the CATCO protocol to include its lead drug candidate.

Notably, CATCO is a controlled trial at up to fifty-five hospitals throughout Canada to identify novel therapies for COVID-19-related problems.

The ARCH stock was down by 0.3 per cent on Monday and closed at C$ 3.05 per share.

Also Read: Lightweights in 2022: 5 junior Canadian stocks to buy in May

Please note, the above content constitutes a very preliminary observation or view based on digital trends and is of limited scope without any in-depth fundamental valuation or technical analysis. Any interest in stocks or sectors should be thoroughly evaluated taking into consideration the associated risks.

Disclaimer

Speak your Mind

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK